Our top pick for
Building a portfolio

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Posted
Black Diamond Therapeutics, Inc is a biotechnology business based in the US. Black Diamond Therapeutics shares (BDTX) are listed on the NASDAQ and all prices are listed in US Dollars. Black Diamond Therapeutics employs 58 staff and has a market cap (total outstanding shares value) of USD$1.2 billion.
Our top pick for
Building a portfolio
Our top pick for
Beginners
Our top pick for
Mobile users
Latest market close | USD$33.38 |
---|---|
52-week range | USD$17.63 - USD$45.9699 |
50-day moving average | USD$33.4561 |
200-day moving average | USD$32.5201 |
Wall St. target price | USD$51 |
PE ratio | N/A |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | USD$-1.0803 |
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $33.38 from 2020-12-09
1 week (2021-01-15) | 23.90% |
---|---|
1 month (2020-12-23) | -1.21% |
3 months (2020-10-23) | 4.77% |
6 months (2020-07-22) | 17.54% |
1 year (2020-01-19) | N/A |
---|---|
2 years (2019-01-19) | N/A |
3 years (2018-01-19) | N/A |
5 years (2016-01-19) | N/A |
Gross profit TTM | USD$0 |
---|---|
Return on assets TTM | -16.6% |
Return on equity TTM | -27.02% |
Profit margin | 0% |
Book value | N/A |
Market capitalisation | USD$1.2 billion |
TTM: trailing 12 months
There are currently 3.0 million Black Diamond Therapeutics shares held short by investors – that's known as Black Diamond Therapeutics's "short interest". This figure is 4.8% down from 3.2 million last month.
There are a few different ways that this level of interest in shorting Black Diamond Therapeutics shares can be evaluated.
Black Diamond Therapeutics's "short interest ratio" (SIR) is the quantity of Black Diamond Therapeutics shares currently shorted divided by the average quantity of Black Diamond Therapeutics shares traded daily (recently around 307364.37941473). Black Diamond Therapeutics's SIR currently stands at 9.91. In other words for every 100,000 Black Diamond Therapeutics shares traded daily on the market, roughly 9910 shares are currently held short.
However Black Diamond Therapeutics's short interest can also be evaluated against the total number of Black Diamond Therapeutics shares, or, against the total number of tradable Black Diamond Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Black Diamond Therapeutics's short interest could be expressed as 0.08% of the outstanding shares (for every 100,000 Black Diamond Therapeutics shares in existence, roughly 80 shares are currently held short) or 0.1176% of the tradable shares (for every 100,000 tradable Black Diamond Therapeutics shares, roughly 118 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Black Diamond Therapeutics.
Find out more about how you can short Black Diamond Therapeutics stock.
We're not expecting Black Diamond Therapeutics to pay a dividend over the next 12 months.
Black Diamond Therapeutics, Inc., a precision oncology medicine company, discovers and develops small molecule, tumor-agnostic therapies. Its lead product candidate is BDTX-189, an inhibitor of non-canonical and oncogenic mutations of ErbB kinases epidermal growth factor receptor (EGFR) and tyrosine-protein kinase. The company is also developing allosteric-EGFR mutation inhibitors; and various early stage pipeline programs targeting allosteric mutations in kinases related to cancer and/or rare genetic diseases. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.
Steps to owning and managing SSNC, with 24-hour and historical pricing before you buy.
Steps to owning and managing SMBC, with 24-hour and historical pricing before you buy.
Steps to owning and managing SMED, with 24-hour and historical pricing before you buy.
Steps to owning and managing SJW, with 24-hour and historical pricing before you buy.
Steps to owning and managing SFBS, with 24-hour and historical pricing before you buy.
Steps to owning and managing LEDS, with 24-hour and historical pricing before you buy.
Steps to owning and managing SC, with 24-hour and historical pricing before you buy.
Steps to owning and managing RTW, with 24-hour and historical pricing before you buy.
Steps to owning and managing RIVE, with 24-hour and historical pricing before you buy.
Steps to owning and managing RVSB, with 24-hour and historical pricing before you buy.